This company listing is no longer active
Terns Pharmaceuticals Management
Management criteria checks 2/4
Terns Pharmaceuticals' CEO is Amy Burroughs, appointed in Feb 2024, has a tenure of 2.25 years. total yearly compensation is $4.59M, comprised of 14.1% salary and 85.9% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €6.64M. The average tenure of the management team and the board of directors is 1.3 years and 3.8 years respectively.
Key information
Amy Burroughs
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 14.05% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$5m | US$645k | -US$96m |
| Sep 30 2025 | n/a | n/a | -US$94m |
| Jun 30 2025 | n/a | n/a | -US$92m |
| Mar 31 2025 | n/a | n/a | -US$90m |
| Dec 31 2024 | US$8m | US$564k | -US$89m |
Compensation vs Market: Amy's total compensation ($USD4.59M) is above average for companies of similar size in the German market ($USD2.80M).
Compensation vs Earnings: Amy's compensation has been consistent with company performance over the past year.
CEO
Amy Burroughs (54 yo)
Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$4.59m | 0.13% € 6.6m | |
| CFO & Head of Corporate Development | 1.3yrs | US$2.61m | 0.029% € 1.5m | |
| Chief Medical Officer | 3yrs | US$2.36m | 0.021% € 1.1m | |
| Chief Development & Operations Officer | less than a year | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Vice President of Marketing | less than a year | no data | no data | |
| Chief People Officer | 1.3yrs | no data | no data | |
| SVP & Senior Distinguished Research Fellow | 4.3yrs | no data | no data | |
| Chief Business Officer | 2.1yrs | US$2.20m | 0.0019% € 101.5k | |
| Senior Vice President of Medical Affairs | 2.3yrs | no data | no data | |
| Senior Vice President of CMC | 1.3yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 1.1yrs | no data | no data |
Experienced Management: 430's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$4.59m | 0.13% € 6.6m | |
| Independent Director | 5.4yrs | US$168.17k | 0% € 0 | |
| Independent Director | 1.5yrs | US$172.33k | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Chairman | 5.4yrs | US$195.73k | 0% € 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.3yrs | US$291.50k | no data | |
| Independent Director | 3.8yrs | US$175.67k | 0% € 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.4yrs | US$176.27k | 0% € 0 |
Experienced Board: 430's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 12:05 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Corinne Johnson | Goldman Sachs |